Semaglutide: Unlock Dramatic Weight Loss Results Today

Semaglutide, sold under the brand names Ozempic and Wegovy, has become one of the most talked-about medications in weight management. Originally developed to treat type 2 diabetes, it’s now widely prescribed specifically for chronic weight management under its own FDA-approved indication.

This guide covers how semaglutide works, what the clinical trial data actually shows, who’s a reasonable candidate, and the real risks worth understanding before starting treatment.

Key Takeaways

Semaglutide (Wegovy) has been FDA-approved for chronic weight management since 2021 — this isn’t a pending or experimental use.
In the STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo; the STEP 5 trial found similar results sustained out to 104 weeks (-15.2% vs. -2.6%).
Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodent studies, and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Gastrointestinal side effects are common, and less frequent but more serious risks include pancreatitis and gallbladder disease (cholelithiasis occurred in 1.6% of Wegovy patients vs. 0.7% on placebo in trials).
Semaglutide is meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone solution — and candidacy depends on a real evaluation of your health history, not just a BMI number.

What Is Semaglutide and How Does It Work?

Semaglutide is a GLP-1 receptor agonist — it mimics a naturally occurring gut hormone that helps regulate blood sugar and appetite. It works by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and signaling fullness to the brain. The combined effect is that people taking it tend to eat less and feel satisfied sooner.

It’s typically administered as a once-weekly subcutaneous injection, with the dose gradually increased over several weeks to reduce gastrointestinal side effects. An oral tablet form also exists, though it requires more frequent dosing to reach a similar steady-state concentration.

How Effective Is Semaglutide for Weight Loss? What the Research Shows

The clinical trial data on semaglutide for weight loss is well-documented. In the STEP 1 trial published in the New England Journal of Medicine, participants taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. The STEP 5 trial found similarly sustained results out to 104 weeks — a 15.2% average reduction versus 2.6% with placebo — suggesting the effect holds up over a longer treatment period, provided the medication is continued.

For comparison, tirzepatide (marketed as Zepbound), a related but distinct medication, showed dose-dependent results in the SURMOUNT-1 trial ranging from 15.0% at the lowest studied dose to 20.9% at the highest, versus 3.1% with placebo, at 72 weeks. Individual results vary significantly based on dose, adherence, and lifestyle factors — these trial averages describe group outcomes, not a guarantee for any one person.

Who Is Semaglutide For?

Wegovy’s FDA-approved indication covers adults with obesity, or adults with overweight plus at least one weight-related health condition (such as high blood pressure, type 2 diabetes, or high cholesterol), to be used alongside a reduced-calorie diet and increased physical activity — not as a standalone solution. The label has since expanded to include additional indications related to cardiovascular risk reduction in certain patients, which underscores that appropriate use depends on an individual health evaluation, not a BMI number alone.

A real candidacy conversation should cover your full medical history, current medications, and health goals — not just whether you meet a weight threshold.

Risks and Who Should Avoid It

Semaglutide carries an FDA boxed warning: in rodent studies, it caused thyroid C-cell tumors, and while it’s unknown whether this occurs in humans, the medication is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation, especially during dose increases. Less common but more serious risks include pancreatitis (discontinue and seek care if severe abdominal pain occurs) and gallbladder disease — cholelithiasis occurred in 1.6% of Wegovy patients in trials, compared to 0.7% on placebo. People with a history of severe gastrointestinal disease should discuss these risks carefully with a provider before starting. Pregnancy is a factor your provider needs to weigh directly, since the medication isn’t recommended during pregnancy and its safety in that context hasn’t been established. Liver injury has not shown up as a clear signal in clinical trials, though rare post-marketing reports exist — worth mentioning to your provider if you have existing liver disease.

Preventive Care and When to Talk to a Provider

If you’re considering semaglutide, the right first step is a real evaluation, not a self-assessment against a BMI chart. Our team can walk you through our medical weight loss program and help you understand whether semaglutide, a different approach, or a combination — including nutritional support tailored to your specific health needs — makes the most sense for you.

Conclusion

Semaglutide has a strong, well-documented evidence base for chronic weight management — the STEP trial data shows real, sustained results for many patients. It also carries real risks and contraindications that deserve a serious conversation with a provider, not just a quick BMI check. The right approach depends on your full health picture, not a single number or a headline statistic.

Take the Next Step

Ready to find out if semaglutide is right for you? Call DrStileRx at (702) 940-9925 or schedule a consultation below.

DrStileRx serves Las Vegas, NV & Surrounding Areas.

*Individual results may vary

Schedule a Consultation

FAQs

Q1. Is semaglutide FDA-approved for weight loss?

Yes. Wegovy (semaglutide) has been FDA-approved for chronic weight management since 2021, for adults with obesity or with overweight plus at least one weight-related health condition, used alongside diet and exercise.

Q2. How much weight can I expect to lose?

In clinical trials, average weight loss was 14.9% of body weight at 68 weeks (STEP 1) and 15.2% at 104 weeks (STEP 5). These are group averages from research studies, not a guarantee — individual results vary based on dose, adherence, and lifestyle factors.

Q3. What are the most serious risks?

Semaglutide carries a boxed warning for thyroid C-cell tumors observed in rodent studies and is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Pancreatitis and gallbladder disease are less common but more serious risks; gastrointestinal side effects like nausea and diarrhea are the most frequently reported.

Q4. Who shouldn’t take semaglutide?

People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome shouldn’t take it. Anyone with a history of pancreatitis, severe gastrointestinal disease, or gallbladder disease should discuss the risks carefully with a provider first, and it isn’t recommended during pregnancy.

Q5. How is semaglutide different from tirzepatide?

Both are injectable medications that work on similar hormonal pathways, but tirzepatide (Zepbound) also acts on a second receptor (GIP) in addition to GLP-1. In its own trial (SURMOUNT-1), tirzepatide showed dose-dependent weight loss of 15.0% to 20.9% at 72 weeks — figures from a different trial with a different patient population than semaglutide’s, so they aren’t a direct head-to-head comparison.

Resources

Dr. Frank L. Stile, MD, FACS

See Full Bio